Lloyd Loft, MD
Otolaryngology · New York, NYNPI 1851490304
Payments from drug & device makers
What this record shows
This record is dominated by other: $12,013 of the $12,298 with a category attached, or 97.7%. Olympus America Inc. accounts for 97.7% of it on its own, with 5 other manufacturers making up the rest. 2024 is the largest year on record at $12,013, more than ten times the $264 reported in 2019. Among otolaryngology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 11 payments — averaging $1117.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$12K
- Optinose US, Inc.$172
- Acclarent, Inc$42
- Stryker$37
- Genentech USA, Inc.$20
- Takeda Pharmaceuticals U.S.A., Inc.$14
What the payments were for
- Food & beverage$2852%
- Other$12,01398%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 1 | $12,013 |
| Optinose US, Inc. | 4 | $172 |
| Acclarent, Inc | 2 | $42 |
| Stryker | 2 | $37 |
| Genentech USA, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,298 in reported general payments places this provider in the 90th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 17 | $1,971 |
| Methylprednisolone | 72 | $573 |
| Ipratropium Bromide | 24 | $500 |
| Azelastine Hcl | 29 | $492 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 51 | $329 |
| Omeprazole | 31 | $241 |
| Mupirocin | 16 | $102 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in New York
- Roheen RaithathaNew York$830K
- Dennis KrausNew York$159K
- Anthony DelsignoreNew York$89K
- Satish GovindarajNew York$39K
- Lawrence LustigNew York$33K
- Justin GolubNew York$30K
- Brett MilesNew York$30K
- David HiltzikNew York$25K
- Milan AminNew York$23K
- Ashutosh KackerNew York$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.